Watson plans OTC switch for EC
This article was originally published in The Tan Sheet
Executive Summary
A next-generation emergency contraceptive could switch to nonprescription status eventually, according to Watson Pharmaceuticals, which licensed ulipristal acetate from HRA Pharma Feb. 1. "Ultimately, I suspect in time we will try to get the product to go OTC, just like the Plan B product," said CEO Paul Bisaro. Bisaro, speaking at the CLSA/Asia USA Investor's Forum in San Francisco March 2, noted UPA demonstrated high effectiveness for five days after unprotected sex. UPA is marketed in Europe as ellaOne by HRA Pharma and is currently in the new drug application stage with FDA
You may also be interested in...
EC competition clears advisory panel
FDA's Advisory Committee for Reproductive Health Drugs June 17 votes unanimously in favor of approving Watson Pharmaceuticals' emergency contraceptive ulipristal acetate, marketed in Europe as ellaOne by HRA Pharma. Collins Stewart analyst Louise Chen said in a same-day note the panel's decision bodes well for FDA approval and a likely early 2011 launch for UPA, which Chen expects to compete with Teva's Plan B One-Step (levonorgestrel). Although UPA would be available Rx-only upon approval, Watson CEO Paul Bisaro has stated an interest in switching the next-generation EC to nonprescription status (1"The Tan Sheet" March 15, 2010, In Brief)
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.